opc 12759 has been researched along with Gastric Diseases in 6 studies
rebamipide: structure in first source; RN refers to (+-)-isomer; inhibits gastric xanthine oxidase
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujimoto, A | 1 |
| Uraoka, T | 1 |
| Nishizawa, T | 1 |
| Shimoda, M | 1 |
| Goto, O | 1 |
| Ochiai, Y | 1 |
| Maehata, T | 1 |
| Akimoto, T | 1 |
| Mitsunaga, Y | 1 |
| Sasaki, M | 1 |
| Yamamoto, H | 1 |
| Yahagi, N | 1 |
| Gagliano-Jucá, T | 1 |
| Moreno, RA | 1 |
| Zaminelli, T | 1 |
| Napolitano, M | 1 |
| Magalhães, AF | 1 |
| Carvalhaes, A | 1 |
| Trevisan, MS | 1 |
| Wallace, JL | 1 |
| De Nucci, G | 1 |
| Kinjo, N | 1 |
| Kawanaka, H | 1 |
| Akahoshi, T | 1 |
| Yamaguchi, S | 1 |
| Yoshida, D | 1 |
| Anegawa, G | 1 |
| Konishi, K | 1 |
| Tomikawa, M | 1 |
| Tanoue, K | 1 |
| Tarnawski, A | 1 |
| Hashizume, M | 1 |
| Maehara, Y | 1 |
| Naito, Y | 1 |
| Yoshikawa, T | 1 |
| Sakurai, K | 1 |
| Yamasaki, K | 1 |
| Watanabe, S | 1 |
| Wang, XE | 1 |
| Hirose, M | 1 |
| Yoshizawa, T | 1 |
| Iwazaki, R | 1 |
| Oide, H | 1 |
| Kitamura, T | 1 |
| Miwa, H | 1 |
| Miyazaki, A | 1 |
| Sato, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-blind Trial on the Gastrointestinal Integrity Evaluation After Daily Naproxen 1100 mg + Rebamipide 200mg for 7 Days Versus Naproxen 1100mg + Placebo for 7 Days[NCT02632812] | Phase 1 | 24 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Cryer score according to gastroduodenal mucosal injury:~0 = Normal or erythema~= Any amount of submucosal hemorrhage or edema without erosions~= 1 erosion +- submucosal hemorrhage or edema~= 2-4 erosions +- submucosal hemorrhage or edema~= 5 or more erosions and/or a single ulcer +- submucosal hemorrhage or edema~= Multiple ulcers +- submucosal hemorrhage or edema - Ulcer" (NCT02632812)
Timeframe: 8 days
| Intervention | Cryer score (Median) |
|---|---|
| Rebamipide & Naproxen | 4 |
| Placebo & Naproxen | 4 |
"Modified Lanza score according to gastroduodenal mucosal injury:~0 = No hemorrhage or erosion observed~= One or two hemorrhages or erosions observed in one gastric area~= Three to five hemorrhages or erosions observed in one gastric area~= Hemorrhages or erosions observed in two gastric areas, six or more hemorrhages or erosions observed in one gastric area, with the total number not exceeding ten in the entire stomach~= Hemorrhages or erosions observed in three or more gastric areas; eleven or more hemorrhages or erosions observed widely in the entire stomach~= Ulcer" (NCT02632812)
Timeframe: 8 days
| Intervention | Modified Lanza score (Median) |
|---|---|
| Rebamipide & Naproxen | 3.5 |
| Placebo & Naproxen | 4 |
(NCT02632812)
Timeframe: 60 days
| Intervention | adverse events (Number) |
|---|---|
| Rebamipide & Naproxen | 7 |
| Placebo & Naproxen | 7 |
"Histopathologic grade score developed for microscopic injury evaluation 0 = Normal gastric mucosa or mild chronic inflammation~= Chronic gastritis without activity~= Chronic gastritis with activity on antrum~= Chronic gastritis with activity on the body~= Chronic gastritis with activity on antrum and on the body" (NCT02632812)
Timeframe: 8 days
| Intervention | Histopathologic grade score (Median) | |
|---|---|---|
| Basal endoscopy | End of treatment endoscopy | |
| Placebo & Naproxen | 1 | 1 |
| Rebamipide & Naproxen | 1 | 1 |
Giemsa stain was used to diagnose H. pylori (positive = presence of H. pylori) (NCT02632812)
Timeframe: 8 days
| Intervention | participants (Number) | |
|---|---|---|
| Basal endoscopy | End of treatment endoscopy | |
| Placebo & Naproxen | 5 | 6 |
| Rebamipide & Naproxen | 5 | 6 |
Tissue prostaglandin concentration quantified by enzyme-linked immunosorbent assay (ELISA) using Cayman Chemical Monoclonal Prostaglandin E2 EIA Kit (item number 514010) (NCT02632812)
Timeframe: 8 days
| Intervention | pg/mL (mean tissue PGE2 concentration) (Mean) | |
|---|---|---|
| Basal PGE2 concentration | End of treatment PGE2 concentration | |
| Placebo & Naproxen | 1005 | 241 |
| Rebamipide & Naproxen | 999 | 168 |
1 review available for opc 12759 and Gastric Diseases
| Article | Year |
|---|---|
Oxidative stress involvement and gene expression in indomethacin-induced gastropathy.
Topics: Alanine; Animals; Anti-Ulcer Agents; Apoptosis; DNA; Gastric Mucosa; Gene Expression Profiling; Gene | 2006 |
1 trial available for opc 12759 and Gastric Diseases
| Article | Year |
|---|---|
Rebamipide does not protect against naproxen-induced gastric damage: a randomized double-blind controlled trial.
Topics: Adolescent; Adult; Alanine; Anti-Inflammatory Agents, Non-Steroidal; Dinoprostone; Double-Blind Meth | 2016 |
4 other studies available for opc 12759 and Gastric Diseases
| Article | Year |
|---|---|
Rebamipide solution: a novel submucosal injection material to promote healing speed and healing quality of ulcers induced by endoscopic submucosal dissection.
Topics: Alanine; Animals; Anti-Ulcer Agents; Endoscopic Mucosal Resection; Female; Fibrosis; Gastric Mucosa; | 2018 |
Significance of ERK nitration in portal hypertensive gastropathy and its therapeutic implications.
Topics: Alanine; Animals; Enzyme Inhibitors; Ethanol; Extracellular Signal-Regulated MAP Kinases; Gastric Mu | 2008 |
Protective effect of rebamipide against hydrogen peroxide-induced hemorrhagic mucosal lesions in rat stomach.
Topics: Alanine; Animals; Gastric Mucosa; Gastrointestinal Hemorrhage; Glutathione; Glutathione Peroxidase; | 1994 |
Effects of rebamipide on bile acid-induced inhibition of gastric epithelial repair in a rabbit cell culture model.
Topics: Actins; Alanine; Animals; Anti-Ulcer Agents; Bromodeoxyuridine; Cell Division; Cell Movement; Cells, | 1996 |